Up a level |
2022
Borchmann, Peter, Vandenberghe, Peter, Urbano-Ispizua, Alvaro, Haioun, Corinne, Lemonnier, Francois, Griskevicius, Laimonas, Maury, Sebastien, Holtkamp, Silke, Friedrichs, Birte, Zadoyan, Gregor, Hanssens, Linda, Overstijns, Toon, Assenmacher, Mario, Bethke, Ulf, Buerger, Iris, Reer, Olaf, Jaeger, Ulrich and Kersten, Marie Jose (2022). Trial in Progress: A Randomized Phase II Study of MB-CART2019.1 Compared to Standard of Care Therapy in Patients with Relapsed/Refractory DLBCL Ineligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation- DALY 2-EU Trial. Blood, 140. S. 12784 - 12786. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
Holzer, Tatjana, Biedermann, Stefanie, Herfort, Inga, Friedrichs, Birte, Holtkamp, Silke, Hanssens, Linda, Assenmacher, Mario, Bethke, Ulf, Schneider, Dina, Miltenyi, Stefan, Overstijns, Toon, Schmid, Christoph, Ayuk, Francis A., Scheid, Christoph, Juehling, Anja, Holtick, Udo, Goedel, Philipp, Borchmann, Peter and Buerger, Iris (2022). Characterization and T-Cell Repertoire of MB-CART2019.1 (Zamtocabtagene autoleucel) - Data from the Phase I Trial in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. Blood, 140. S. 4581 - 4584. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
Kutsch, Nadine, Goedel, Philipp, Holtick, Udo, Lohneis, Anja, Vucinic, Vladan, Altefrohne, Florentine Pia, Schubert, Christin, Karitzky, Sandra, Hanssens, Linda, Assenmacher, Mario, Buerger, Iris, Aktas, Murat and Borchmann, Peter (2022). A Phase I Dose Finding Trial of MB-CART20.1 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. Blood, 140. S. 12980 - 12982. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
2019
Aleksandrova, Krasimira, Leise, Jana, Priesner, Christoph, Melk, Anette, Kubaink, Fanni, Abken, Hinrich, Hombach, Andreas, Aktas, Murat, Essl, Mike, Buerger, Iris, Kaiser, Andrew, Rauser, Georg, Jurk, Marion, Goudeva, Lilia, Glienke, Wolfgang, Arseniev, Lubomir, Esser, Ruth and Koehl, Ulrike (2019). Functionality and Cell Senescence of CD4/CD8-Selected CD20 CAR T Cells Manufactured Using the Automated CliniMACS Prodigy (R) Platform. Transfus. Med. Hemother., 46 (1). S. 47 - 55. BASEL: KARGER. ISSN 1660-3818